Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism IL-23 inhibitors(Interleukin-23 inhibitors), α4β7 antagonists(Integrin alpha-4/beta-7 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory Bowel Diseases | Preclinical | US | 10 Oct 2023 |